Common TitleTMC125-C223
Official Title A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of Etravirine (TMC125) in HIV-1 Infected Subjects With Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations
Phase Phase IIB
ClinicalTrials.gov NCT00081978
Treatments
Etravirine
Etravirine
Tradename:IntelenceOther Names:ETRClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)Categories Resistance/Virological FailureTreatment-Experienced
Funding
IndustryTibotec Pharmaceuticals, Ireland
References
- Cohen CJ, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial. AIDS. 2009;23:423-6.
- TMC125-C223 Writing Group, Nadler JP, Berger DS, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS. 2007;21:F1-10.